Leveraging the FAERS Public Dashboard for Proactive Cosmetic Safety Monitoring

The New Transparency Paradigm Under MoCRA

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) fundamentally altered the compliance calculus for cosmetics manufacturers, packers, and distributors. For the first time, "responsible persons" under the Federal Food, Drug, and Cosmetic Act face mandatory serious adverse event reporting obligations, strict recordkeeping duties, and an FDA armed with new mandatory recall authority. These statutory changes did not occur in a vacuum. They were accompanied by a broader FDA institutional commitment to surveillance transparency—most visibly through publicly accessible adverse event dashboards built on the same architecture FDA has long used for pharmaceuticals.

A preliminary clarification is warranted for precision. Industry professionals frequently use "FAERS" as shorthand for FDA's adverse event surveillance infrastructure generally, though the dashboard most directly relevant to cosmetic products operates under FDA's Center for Food Safety and Applied Nutrition (CFSAN) rather than the drug-centric Center for Drug Evaluation and Research system. Regardless of nomenclature, the operative point for cosmetics companies is the same: FDA now makes granular, searchable adverse event data publicly available in near real time, and sophisticated market participants—plaintiffs' counsel, competitors, journalists, and FDA investigators alike—are already mining it.

Why the Dashboard Changes the Risk Calculus

Before MoCRA, cosmetic adverse event reporting to FDA was largely voluntary, and the resulting data was sparse and difficult to analyze. That era has ended. Companies now operate in an environment where:

• Serious adverse events must be reported to FDA within a defined statutory window following receipt.
• Underlying records must be retained and made available to FDA upon request.
• The aggregated data populating the public dashboard is accessible to anyone with internet access—not just regulators.

This convergence of mandatory reporting and public accessibility means that safety signals affecting a company's products, its direct competitors, or an entire product category can surface publicly before the company itself has internally escalated the issue. A responsible person who learns about an emerging trend from a plaintiff's demand letter or a trade press article—rather than from its own monitoring protocol—has already lost the initiative in any subsequent regulatory or litigation posture.

From Reactive Compliance to Predictive Risk Management

The strategic opportunity here is not merely defensive. Companies that systematically monitor public adverse event data can identify emerging safety trends while they are still statistically marginal, long before they reach the threshold that would trigger FDA inquiry, media attention, or a mandatory recall determination. This is the essence of proactive risk management: using publicly available surveillance data as an early warning system rather than waiting for enforcement correspondence.

Practical applications include:

• Ingredient-level trend analysis. Monitoring reports associated with specific ingredients or formulation categories—particularly those that have drawn regulatory or scientific scrutiny in recent years, such as certain preservatives, chemical UV filters, and specific hair care formulations—allows a company to assess whether its own products share exposure to a developing concern.
• Category benchmarking. Comparing a company's own adverse event frequency against broader category trends helps distinguish an isolated manufacturing or labeling issue from a sector-wide phenomenon, which materially affects the appropriate remediation strategy.
• Competitive and supply chain intelligence. Adverse events linked to a shared ingredient supplier or contract manufacturer may surface in reports concerning a competitor's product before they appear in a company's own complaint files.
• Substantiation file support. Documented, periodic dashboard review can serve as contemporaneous evidence that the responsible person is actively monitoring safety signals consistent with its statutory safety substantiation obligations.

Building a Dashboard Monitoring Protocol

Treating public adverse event data as a compliance input requires deliberate process design rather than ad hoc review. Boutique and mid-market cosmetics companies without the surveillance infrastructure of large pharmaceutical sponsors should consider the following framework:

• Assign ownership. Designate a specific individual or cross-functional team—typically regulatory affairs, quality, and legal—responsible for periodic dashboard review, with a defined cadence (monthly, at minimum, for companies with higher-risk product lines).
• Define escalation triggers. Establish objective criteria for when a dashboard observation requires escalation to senior management or outside counsel, such as a statistically notable increase in reports, a new category of harm, or reports implicating a shared ingredient across multiple products.
• Integrate with existing complaint-handling systems. Dashboard findings should be cross-referenced against internal complaint logs to identify discrepancies between what customers report directly to the company and what ultimately appears in FDA's public data.
• Document the review. Maintain a written record of each review cycle, findings, and any resulting action (or reasoned decision not to act). This documentation is invaluable if FDA later questions the adequacy of a company's safety monitoring program.
• Incorporate into due diligence. Companies engaged in M&A, private equity transactions, or supplier qualification should integrate dashboard review into standard diligence checklists for target products and ingredients.

The Enforcement Context

FDA has signaled, through its rulemaking activity and public statements implementing MoCRA, that adverse event data will inform its risk-based inspection and enforcement priorities. A company that can demonstrate a documented, proactive monitoring protocol—rather than reactive scrambling after an FDA inquiry—occupies a materially stronger position in any subsequent warning letter response, recall negotiation, or civil litigation. Regulators and plaintiffs' counsel increasingly expect sophisticated market participants to be monitoring the same public data FDA itself relies upon; failure to do so can be characterized as a gap in reasonable diligence.

Key Recommendations

• Build dashboard review into existing MoCRA compliance infrastructure rather than treating it as a standalone exercise.
• Calibrate monitoring frequency and scope to the company's risk profile, giving particular attention to higher-scrutiny ingredient categories.
• Preserve documentation of monitoring activity as part of the company's broader safety substantiation and recordkeeping obligations.
• Involve legal counsel early when dashboard trends intersect with existing or anticipated litigation exposure.

Companies that treat FDA's public adverse event surveillance data as a standing component of enterprise risk management—rather than an afterthought—will be better positioned to identify emerging safety concerns, respond credibly to regulatory inquiries, and avoid the reputational and financial costs of reactive crisis management.